FGFRs antagonists(Fibroblast growth factor receptors antagonists), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors), HPK1 inhibitors(Mitogen-activated protein kinase kinase kinase kinase 1 inhibitors)

+ [3]

Therapeutic Areas

NeoplasmsDigestive System DisordersHemic and Lymphatic Diseases+ [2]

Active Indication

Advanced gastric carcinomaColorectal CancerMyelodysplastic Syndromes+ [4]

Inactive Indication

Advanced Colorectal AdenocarcinomaAdvanced Gastric AdenocarcinomaGastrooesophageal junction cancer+ [1]

Originator Organization

Guangzhou Zaiji Medical Technology Co., Ltd.

Active Organization

Guangzhou Zaiji Medical Technology Co., Ltd.

Inactive Organization

Maxinovel Pty., Ltd.

Drug Highest PhasePhase 2

First Approval Date-

RegulationSpecial Review Project (CN), Orphan Drug (US)

Structure

Molecular FormulaC22H23FN6OS

InChIKeyAVIOBQFPAGEICQ-UHFFFAOYSA-N

CAS Registry2070931-57-4

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15191

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced gastric carcinoma	Phase 2	CN	Guangzhou Zaiji Medical Technology Co., Ltd.	25 Jun 2022
Colorectal Cancer	Phase 2	CN	Guangzhou Zaiji Medical Technology Co., Ltd.	29 Nov 2021
Myelodysplastic Syndromes	Phase 2	CN	Guangzhou Zaiji Medical Technology Co., Ltd.	09 Sep 2021
Refractory acute myeloid leukemia	Phase 2	CN	Guangzhou Zaiji Medical Technology Co., Ltd.	09 Sep 2021
Relapsing acute myeloid leukemia	Phase 2	CN	Guangzhou Zaiji Medical Technology Co., Ltd.	09 Sep 2021
Advanced Gastric Adenocarcinoma	Discovery	CN	Maxinovel Pty., Ltd.	01 Jun 2022
Gastrooesophageal junction cancer	Discovery	CN	Maxinovel Pty., Ltd.	01 Jun 2022
Advanced Colorectal Adenocarcinoma	Discovery	CN	Maxinovel Pty., Ltd.	31 Jan 2022
Metastatic Colorectal Carcinoma	Discovery	CN	Maxinovel Pty., Ltd.	31 Jan 2022
Acute Myeloid Leukemia	Discovery	AU	Maxinovel Pty., Ltd.	01 Aug 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Company_Website Manual	Phase 1	Acute Myeloid Leukemia FLT3野生型	-	MAX-40279+阿扎胞苷	(lveyzsonfn) = stplupkuqv qffnuuyoef (fbgkzcerni ) View more	Positive	01 Oct 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis